Related Experiment Videos
MDR1 gene expression in lung cancer.
S L Lai1, L J Goldstein, M M Gottesman
1NCI-Navy Medical Oncology Branch, Naval Hospital, Bethesda, MD 20814.
Journal of the National Cancer Institute
|August 2, 1989
Summary
Multidrug resistance (MDR) gene expression, also known as P-glycoprotein 1 (PGY1), is not solely responsible for multidrug resistance in lung cancer. Studies show low MDR1 gene expression in most lung tumors and cell lines, with no correlation to treatment outcomes.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- The MDR1 gene (also known as PGY1) is implicated in multidrug resistance.
- Overexpression of MDR1 is observed in various multidrug-resistant cell lines.
- Its role in lung cancer requires further investigation.
Purpose of the Study:
- To investigate the role of MDR1 gene expression in lung cancer.
- To determine the correlation between MDR1 expression and chemosensitivity or clinical response in lung cancer patients.
Main Methods:
- RNA slot blot analysis was performed on lung cancer samples, adjacent non-tumorous lung tissues, and lung cancer cell lines.
- Analysis included 24 lung cancers, 10 non-tumorous lung tissues, and 67 cell lines.
- MDR1 gene amplification and rearrangements were also assessed.
Main Results:
- Low levels of MDR1 RNA were detected in most tumors, non-tumorous lung tissues, and cell lines.
- Higher MDR1 expression was observed in a subgroup of non-small cell lung cancers with neuroendocrine markers.
- No correlation was found between MDR1 gene expression and in vitro chemosensitivity, prior therapy, or clinical response.
Conclusions:
- MDR1 gene expression alone does not explain the clinical multidrug resistance observed in many lung cancers.
- The findings suggest other mechanisms contribute to multidrug resistance in lung cancer.
- Further research is needed to elucidate the complex mechanisms of drug resistance in lung cancer.